Director, Patient Advocacy & Society Engagement, Europe

Das ist der Job

The Opportunity Lead, design, and implement RevMed’s EAP work in the Europe Region across all assets.

Darum lohnt es sich

As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. Serve as the primary point of contact for EAP core and extended teams as well as vendor management.

Play an instrumental role in supporting teams in understanding impacts of EAP on other clinical programs. Revolution Medicines is a late‑stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers.

The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.

The company’s RAS(ON) inhibitors daraxonrasib (RMC‑6236), a RAS(ON) multi‑selective inhibitor; elironrasib (RMC‑6291), a RAS(ON) G12C‑selective inhibitor; zoldonrasib (RMC‑9805), a RAS(ON) G12D‑selective inhibitor; and RMC‑5127, a RAS(ON) G12V‑selective inhibitor, are currently in clinical development.

Serve as the primary point of accountability to develop long‑term, trusting relationships across patient and professional societies in the Europe region. Compliantly engage partners to share insights in support of best patient outcomes.

Partner with the VP, Communications, Public Affairs and Policy Advocacy, Europe, supporting compliant interactions with HTA bodies. Support creation and execution of internal patient engagement p